{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T15:04:04Z","timestamp":1789311844448,"version":"build-2803163510"},"reference-count":52,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"mylife Diabetes Care AG"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"abstract":"<jats:sec>\n                    <jats:title>Background and Aims:<\/jats:title>\n                    <jats:p>Automated Insulin Delivery (AID) systems are the recommended standard of care for Type 1 Diabetes (T1D) management in children and adolescents, according to latest international guidelines. This study aims to assess the cost-effectiveness of AID systems for pediatric T1D care in Australia, Canada, the United Kingdom (UK), and the United States (USA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      The IQVIA Core Diabetes Model was used to compare AID systems with Multiple Daily Injections and Continuous Glucose Monitoring (MDI+CGM). Data were sourced from the National Health System (NHS\n                      <jats:bold>)<\/jats:bold>\n                      England real-world AID pilot initiative, a prospective follow-up study of 251 children and adolescents with T1D that showed a 0.63% reduction in HbA1c following the first year of system use. Clinical and economic outcomes were analyzed over a 55-year time horizon from a health care system perspective, applying country-specific discount rates and direct costs to estimate cost-effectiveness ratios (ICERs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>AID systems were associated with Quality-Adjusted Life Years (QALYs) gains ranging from 1.35 to 2.72 across all countries. AID use resulted in significant relative risk reduction for long-term complications, such as proliferative diabetic retinopathy (51.3%), end-stage renal disease (39.5%), and severe vision loss (38.8%). Total cost savings ranged from USD\u20149340 in Australia to USD\u201428,798 in Canada. AID use was associated with an ICER of 14,590 in Australia, 25,798 in Canada, 32,459 in the UK, and 35,648 in USA per QALY gained (all values in USD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>AID therapy was predicted to reduce mid- and long-term diabetes-related complications and improve quality of life while concomitantly reducing the economic burden on health care systems. AID was projected to be cost-effective versus MDI+CGM for pediatrics and adolescents with T1D in all analyzed countries. These findings highlight the need to accelerate the adoption of AID systems and to secure universal access and funding during this vulnerable period of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15209156261486122","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:15:27Z","timestamp":1789031727000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Clinical and Economic Impact of Automated Insulin Delivery Systems Use in Pediatric and Adolescents Type 1 Diabetes: Results Across Australia, Canada, the UK, and the USA"],"prefix":"10.1177","author":[{"given":"Laurent","family":"Legault","sequence":"first","affiliation":[{"name":"Pediatric Endocrinology Division, Department of Pediatrics, McGill University, Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Sherr","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatric Endocrinology, Yale School of Medicine, New Haven, Connecticut, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Davis","sequence":"additional","affiliation":[{"name":"Children\u2019s Diabetes Centre, The Kids Research Institute Australia, University of Western Australia, Perth, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Cerezales","sequence":"additional","affiliation":[{"name":"Axentiva Solutions, Oviedo, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aesha","family":"Khan Mir\u00f3n","sequence":"additional","affiliation":[{"name":"mylife Diabetes Care AG, Burgdorf, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2883-9679","authenticated-orcid":false,"given":"Maria-Eleni","family":"Syleouni","sequence":"additional","affiliation":[{"name":"mylife Diabetes Care AG, Burgdorf, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze May","family":"Ng","sequence":"additional","affiliation":[{"name":"Faculty of Health, Social Care and Medicine, Edge Hill University, Lancashire, United Kingdom."},{"name":"Paediatric Department, Mersey and West Lancashire Teaching Hospitals NHS, Southport, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"e_1_3_3_2_1","volume-title":"IDF diabetes atlas","author":"Dianna Magliano","year":"2021","unstructured":"1.Dianna Magliano, , Boyko EJ. IDF diabetes atlas. International Diabetes Federation; 2021."},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.16107"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/db14-1445"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4610-6"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.DIABET.2020.09.001"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/S11892-021-01400-9"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02317-1"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S014"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000543266"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/DIA.2018.0384"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/PEDI.13364"},{"key":"e_1_3_3_13_1","volume-title":"2017-21 Adolescent and Young Adult Type 1 Diabetes","author":"National Diabetes Audit","year":"2021","unstructured":"12.National Diabetes Audit. 2017-21 Adolescent and Young Adult Type 1 Diabetes. National Diabetes Audit; 2021."},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1155\/pedi\/6920068"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00279-1"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJCB.2023.151329"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/S13300-023-01394-5"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1932296816665635"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000543034"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.3310\/JYPL3536"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/19322968241231950"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2019"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.22331"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/S12916-024-03396-X"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15015"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X1980"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.07.007"},{"key":"e_1_3_3_28_1","unstructured":"27.National Institute for Health and Care Excellence (NICE). Dexcom G6 for real-time continuous glucose monitoring [Internet]. 2020 Nov [cited 2026 Aug 17]. Available from: www.nice.org.uk\/guidance\/mib233"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.2337\/DIACARE.22.1.99"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1990"},{"key":"e_1_3_3_31_1","volume-title":"Review of base-case discount rate in the PBAC Guidelines","year":"2022","unstructured":"30.Review of base-case discount rate in the PBAC Guidelines. PBS News; 2022."},{"key":"e_1_3_3_32_1","unstructured":"31.CADTH. Guidelines for the Economic Evaluation of Health Technologies: Canada. CADTH; 2017. Available from: https:\/\/www.cda-amc.ca\/sites\/default\/files\/pdf\/economic_guidelines_worked_example.pdf [Last accessed: September 23 2025]."},{"key":"e_1_3_3_33_1","volume-title":"Economic evaluation. NICE health technology evaluations: the manual. Guidance","author":"NICE","year":"2022","unstructured":"32.NICE. Economic evaluation. NICE health technology evaluations: the manual. Guidance. NICE; 2022."},{"key":"e_1_3_3_34_1","unstructured":"33.HERC: Measuring Costs for Cost-Effectiveness Analysis. 2025. Available from: https:\/\/www.herc.research.va.gov\/include\/page.asp?id=measure-costs-cea [Last accessed: September 23 2025]."},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.09.36"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/DC23-1765"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.04.014"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JVAL.2018.01.017"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2011.10.006"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.2337\/DC21-2341"},{"key":"e_1_3_3_41_1","unstructured":"40.Ryczek E Baker H Gillies H Metcalfe K Howard D Jones C. The Use of QALYs in Decision-Making in Europe Canada and the US: A Qualitative Review of Methodological Guidance. Available from: https:\/\/www.ispor.org\/docs\/default-source\/cti-meeting-21021-documents\/3f952ab5-029e-4321-acce-dedad1ea99d0.pdf?sfvrsn=a4b9694c_0 [Last accessed: September 29 2025]."},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31506-X"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(20)30339-4"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70514"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00115.2024"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12942"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112329"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16426"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2024.0366"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.10464"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-2033"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2025-004935"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15209156261486122","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15209156261486122","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15209156261486122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T14:18:44Z","timestamp":1789309124000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15209156261486122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":52,"alternative-id":["10.1177\/15209156261486122"],"URL":"https:\/\/doi.org\/10.1177\/15209156261486122","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"15209156261486122"}}